Phio Pharmaceuticals Corp Market Cap ($10.49 Million)
Market Cap & Net Worth: Phio Pharmaceuticals Corp (PHIO)
Phio Pharmaceuticals Corp market cap. Phio Pharmaceuticals Corp (NASDAQ:PHIO) has a market capitalization of $10.49 Million ($10.49 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26807 globally and #5582 in its home market, demonstrating a 6.21% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Phio Pharmaceuticals Corp's stock price $0.90 by its total outstanding shares 11617250 (11.62 Million). Also see PHIO operating cash flow for how efficiently the company converts equity into cash flow.
Phio Pharmaceuticals Corp Market Cap History (2015–2026)
Phio Pharmaceuticals Corp market cap history from 2015 to 2026. Data shows change from $2.64 Trillion to $10.49 Million (-67.97% CAGR). Check Phio Pharmaceuticals Corp (PHIO) stock price for real-time trading data and today's change.
Index Memberships
Phio Pharmaceuticals Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #749 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2446 of 3165 |
Weight: Phio Pharmaceuticals Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Phio Pharmaceuticals Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Phio Pharmaceuticals Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore PHIO net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
773737.61x
Phio Pharmaceuticals Corp's market cap is 773737.61 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $493.19 Billion | $19.00K | -$8.99 Million | 25957301.16x | N/A |
| 2017 | $383.54 Billion | $15.00K | -$12.45 Million | 25569172.50x | N/A |
| 2018 | $22.77 Billion | $138.00K | -$7.36 Million | 164965.30x | N/A |
| 2019 | $11.80 Billion | $21.00K | -$8.84 Million | 561909.45x | N/A |
| 2020 | $3.38 Billion | $4.36K | -$8.79 Million | 773737.61x | N/A |
Competitor Companies of PHIO by Market Capitalization
Companies near Phio Pharmaceuticals Corp in the global market cap rankings as of November 4, 2026. Also see PHIO current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Phio Pharmaceuticals Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Phio Pharmaceuticals Corp (2015–2026)
Market capitalization of Phio Pharmaceuticals Corp from 2015 to today. Between 2015 and today, Phio Pharmaceuticals Corp's market cap moved from $2.64 Trillion to $ 10.49 Million, with a yearly change of -67.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $10.49 Million | -14.00% |
| 2025 | $12.20 Million | -41.67% |
| 2024 | $20.91 Million | -73.68% |
| 2023 | $79.46 Million | -82.97% |
| 2022 | $466.73 Million | -62.80% |
| 2021 | $1.25 Billion | -62.83% |
| 2020 | $3.38 Billion | -71.40% |
| 2019 | $11.80 Billion | -48.17% |
| 2018 | $22.77 Billion | -94.06% |
| 2017 | $383.54 Billion | -22.23% |
| 2016 | $493.19 Billion | -81.29% |
| 2015 | $2.64 Trillion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Phio Pharmaceuticals Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.49 Million USD |
| MoneyControl | $10.49 Million USD |
| MarketWatch | $10.49 Million USD |
| marketcap.company | $10.49 Million USD |
| Reuters | $10.49 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene ex… Read more